Head of Early-Stage Formulation & Drug Product

Kymera Therapeutics; Boston (MA); On-site; USD 235,000 - 330,000; Full time

Benefits offered by this job

Competitive compensation

Annual bonus eligibility

Equity participation

Comprehensive benefits

Job summary

Kymera Therapeutics seeks a Senior Director of Formulation Development to lead preformulation and early formation activities across our small molecule programs. You will drive enabling formulation strategies from candidate selection through IND, partnering with R&D, DMPK, and CMC to advance programs in a fast-paced biotech environment.

We value deep expertise in early-stage pharmaceutical development, preformulation, biopharmaceutics, and enabling formulation technologies to improve solubility

Qualifications

• PhD in Pharmaceutics, Pharmaceutical Sciences, Chemical Engineering, or related field.
• 15+ years of relevant pharmaceutical industry experience, focused on early-stage formulation development.
• Strong understanding of preformulation, biopharmaceutics, formulation development, and oral solid dose manufacturing.

Responsibilities

• Lead early formulation development activities across programs, providing scientific direction on preformulation characterization and enabling formulation strategies.
• Drive reformulation and drug product development strategies for preclinical toxicology and early clinical programs.
• Coordinate with external CROs and CDMOs to execute formulation development objectives.
• Ensure compliance with GMP and regulatory requirements.
• Support CMC regulatory strategy and IND preparation for drug products.

Skills

Preformulation

Biopharmaceutics

Formulation development

IND readiness

External collaboration

GMP knowledge

CRO/CDMO coordination

Education

PhD in Pharmaceutics

Job description

Kymera Therapeutics seeks a Senior Director of Formulation Development to lead preformulation and early formation activities across our small molecule programs. You will drive enabling formulation strategies from candidate selection through IND, partnering with R&D, DMPK, and CMC to advance programs in a fast-paced biotech environment.

We value deep expertise in early-stage pharmaceutical development, preformulation, biopharmaceutics, and enabling formulation technologies to improve solubility